JPH10506791A - 治療用送達系としての微生物 - Google Patents

治療用送達系としての微生物

Info

Publication number
JPH10506791A
JPH10506791A JP8512318A JP51231896A JPH10506791A JP H10506791 A JPH10506791 A JP H10506791A JP 8512318 A JP8512318 A JP 8512318A JP 51231896 A JP51231896 A JP 51231896A JP H10506791 A JPH10506791 A JP H10506791A
Authority
JP
Japan
Prior art keywords
protein
lactobacillus
bacillus
bacillus subtilis
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP8512318A
Other languages
English (en)
Japanese (ja)
Inventor
アルド タグリアブエ，
デイアナ ボラシ，
パオラ ボツス，
ジヨバンニ マツキア，
ジヨバンニ マウリツツイ，
ステフアノ ポルツイオ，
パオロ ルツジーロ，
Original Assignee
ドンペ・ソチエタ・ペル・アチオニ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドンペ・ソチエタ・ペル・アチオニ filed Critical ドンペ・ソチエタ・ペル・アチオニ
Publication of JPH10506791A publication Critical patent/JPH10506791A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP8512318A 1994-10-05 1995-10-04 治療用送達系としての微生物 Pending JPH10506791A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT94A002025 1994-10-05
ITMI942025A IT1270123B (it) 1994-10-05 1994-10-05 Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
PCT/EP1995/003921 WO1996011277A1 (fr) 1994-10-05 1995-10-04 Micro-organismes utilises en tant que systemes d'apport de composes therapeutiques

Publications (1)

Publication Number Publication Date
JPH10506791A true JPH10506791A (ja) 1998-07-07

Family

ID=11369649

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8512318A Pending JPH10506791A (ja) 1994-10-05 1995-10-04 治療用送達系としての微生物

Country Status (6)

Country Link
EP (1) EP0784689A1 (fr)
JP (1) JPH10506791A (fr)
AU (1) AU3745395A (fr)
CA (1) CA2201721A1 (fr)
IT (1) IT1270123B (fr)
WO (1) WO1996011277A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002528392A (ja) * 1998-10-20 2002-09-03 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー 大腸炎処置のためのサイトカイン産生性ラクトコッカス株の使用
JP2003504025A (ja) * 1999-07-05 2003-02-04 フラームス・インテルウニフェルシタイル・インスティチュート・フォール・ビオテヒノロヒー トレフォイルペプチドの送達
WO2006028214A1 (fr) 2004-09-10 2006-03-16 Asahi Glass Company, Limited Vaccin pour administration orale
JP2008067708A (ja) * 1995-10-20 2008-03-27 Actogenix Nv 生物学的に活性のあるポリペプチドのデリバリー
JP2013517256A (ja) * 2010-01-14 2013-05-16 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 炎症性腸疾患（ｉｂｄ）及び過敏性腸症候群（ｉｂｓ）の予防及び治療のための組換体プロバイオティック細菌

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190657B1 (en) 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
CN1253551C (zh) 1997-09-10 2006-04-26 维昂药品公司 减毒的遗传修饰肿瘤靶向细菌
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
FR2791998B1 (fr) * 1999-04-07 2001-06-08 Agronomique Inst Nat Rech Lactocoques modifies exprimant une catalase et leurs utilisations
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
US7569218B2 (en) * 2000-07-27 2009-08-04 The Trustees Of The University Of Pennsylvania Compositions for and methods of using herpes simplex virus glycoprotein D to suppress immune responses
US20020054865A1 (en) 2000-09-21 2002-05-09 Minoru Fujimori Anaerobic bacterium as a drug for cancer gene therapy
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
AU2003210688A1 (en) * 2002-01-31 2003-09-02 Symbigene, Inc. Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
WO2004007695A2 (fr) * 2002-03-08 2004-01-22 Osel, Inc. Lactobacilles exprimant des polypeptides biologiquement actifs et leurs utilisations
JP2005529622A (ja) 2002-06-19 2005-10-06 ヴェーイーベー・ヴェーゼットウェー 腸吸収を促進するための方法および手段
EP1590443A4 (fr) * 2003-01-29 2009-01-07 Osel Inc Expression de surface de proteines biologiquement actives dans des bacteries
ATE511848T1 (de) 2004-08-25 2011-06-15 Us Gov Health & Human Serv Lebendige mikrobielle mikrobizide
WO2006083516A2 (fr) 2005-01-12 2006-08-10 Osel, Inc. Polypeptide de cyanovirine-n modifie
ES2405552T3 (es) 2005-11-29 2013-05-31 Actogenix N.V. Inducción de tolerancia mucosa a antiantígenos de células beta de islotes pancreáticos
EP2016178B1 (fr) * 2006-05-02 2017-07-12 Intrexon Actobiotics NV Administration intestinale microbienne de peptides associés a l'obésité
AU2008204442B2 (en) 2007-01-12 2013-03-14 Intrexon Actobiotics Nv Lactococcus promoters and uses thereof
WO2008090223A2 (fr) 2007-01-25 2008-07-31 Actogenix N.V. Traitement d'une maladie immunitaire par l'administration mucosale d'antigènes
EP3181682B1 (fr) 2008-09-29 2021-04-21 Intrexon Actobiotics NV Colonisation réduite de microbes au niveau de la muqueuse
CA2760248C (fr) 2009-04-30 2019-05-28 Actogenix Nv Cryoprotecteurs pour la lyophilisation de bacteries lactiques
US20120183503A1 (en) 2009-09-29 2012-07-19 Actogenix N.V. Lactobacillus and streptococcus promoters and uses thereof
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
FR2960001A1 (fr) * 2010-05-12 2011-11-18 Univ Rennes Vecteur recombinant pour la production et la secretion de sequences d'acides amines d'interet par les bacteries propioniques et ses applications
US9476056B2 (en) 2010-05-12 2016-10-25 Universite De Rennes 1 Recombinant vector for producing and secreting peptide or protein of interest by propionibacteria and applications thereof
CA2802994A1 (fr) 2010-06-17 2011-12-22 The United States Of America As Represented By The Secretary, National I Nstitutes Of Health Compositions et procedes pour traiter des affections inflammatoires
CN101921725B (zh) * 2010-07-27 2013-06-05 浙江大学 一种口服免疫阻断鸡生长抑素作用的转化子及其应用
JP6117212B2 (ja) 2011-09-23 2017-04-19 イントレクソン・アクトバイオテイクス・エヌブイＩｎｔｒｅｘｏｎ Ａｃｔｏｂｉｏｔｉｃｓ ＮＶ 改変されたグラム陽性菌及びその使用
HUE038336T2 (hu) 2011-09-23 2018-10-29 Intrexon Actobiotics Nv Módosított gram-pozitív baktériumok és alkalmazásaik
MX2015001751A (es) 2012-08-07 2015-11-13 Topgenix Inc Composicion topica comprendiendo bacterias transformadas que expresan un compuesto de interes.
WO2015195546A1 (fr) 2014-06-17 2015-12-23 TopGeniX, Inc. Formulations topiques de protection contre les uv
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
SG11202109537WA (en) 2019-03-04 2021-09-29 Celloryx AG Chloride-inducible prokaryotic expression system

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1321962C (fr) * 1985-03-20 1993-09-07 Aizo Matsushiro Preparations pour prevenir la carie dentaire et mode de preparation

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008067708A (ja) * 1995-10-20 2008-03-27 Actogenix Nv 生物学的に活性のあるポリペプチドのデリバリー
JP2002528392A (ja) * 1998-10-20 2002-09-03 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー 大腸炎処置のためのサイトカイン産生性ラクトコッカス株の使用
JP2010222364A (ja) * 1998-10-20 2010-10-07 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 大腸炎処置のためのサイトカイン産生性ラクトコッカス株の使用
JP2003504025A (ja) * 1999-07-05 2003-02-04 フラームス・インテルウニフェルシタイル・インスティチュート・フォール・ビオテヒノロヒー トレフォイルペプチドの送達
WO2006028214A1 (fr) 2004-09-10 2006-03-16 Asahi Glass Company, Limited Vaccin pour administration orale
US8282936B2 (en) 2004-09-10 2012-10-09 Asahi Glass Company, Ltd. Human papillomavirus vaccine for oral administration
JP2013517256A (ja) * 2010-01-14 2013-05-16 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 炎症性腸疾患（ｉｂｄ）及び過敏性腸症候群（ｉｂｓ）の予防及び治療のための組換体プロバイオティック細菌

Also Published As

Publication number Publication date
ITMI942025A0 (it) 1994-10-05
IT1270123B (it) 1997-04-28
ITMI942025A1 (it) 1996-04-05
EP0784689A1 (fr) 1997-07-23
AU3745395A (en) 1996-05-02
WO1996011277A1 (fr) 1996-04-18
CA2201721A1 (fr) 1996-04-18

Similar Documents

Publication Publication Date Title
JPH10506791A (ja) 治療用送達系としての微生物
ES2351349T3 (es) Liberación de péptidos trébol.
EP2344626B1 (fr) Colonisation réduite de microbes au niveau de la muqueuse
CN101605900B (zh) 乳球菌启动子和其用途
US20040106564A1 (en) Use of slpi for treating chronic inflammatory intestinal diseases
US5922583A (en) Methods for production of recombinant plasmids
AU704594B2 (en) Production of recombinant peptides as natural hydrophobic peptide analogues
US20120183503A1 (en) Lactobacillus and streptococcus promoters and uses thereof
JP2001526533A (ja) λ様プロモーターを有する遺伝子の誘導性発現のための調節系
MXPA06000264A (es) Expresion recombinante de cisteina proteasa de streptococcus pyogenes y composiciones inmunogenicas de las mismas.
AU2003249855B2 (en) Cell wall mutants for delivery of biologically active compounds
JP3288373B2 (ja) 安定および生体活性改変ソマトトロピン類
AU2002357406B2 (en) Defective entities and uses therefor
CN120464662A (zh) 一种表达环二腺苷酸的乳酸乳球菌重组菌及其应用
WO2009020577A2 (fr) Formulation innovante pour la délivrance orale d'insuline
NZ533920A (en) Defective entities and uses therefor